IP Library Granted Patent US 8,545,874
Granted Patent B2
US 8,545,874 · App. 12/772,838 · Granted Oct 1, 2013

Method for making nanolipidic particles

Inventor: Michael W. Fountain (Tampa, FL)
Assignee: Dermazone Solutions, Inc.
A61K8/14A61K8/553A61K9/5107A61K31/375A61Q19/00Y10S977/906Y10S977/907
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,545,874
App. No.
12/772,838
Granted
Oct 1, 2013
Kind
B2
Abstract

Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

Claims (11)

1. A method for making an NLP (Nanolipidic Particle) assembly population, comprising the steps of:

(a) diluting a monophasic optically clear precursor solution with an ethanol solvent to form solvent diluted stock solution; wherein said diluting of said precursor solution with said ethanol solvent is at a ratio ranging from about 1 part precursor to about 20 parts solvent to a ratio ranging from about 1 part precursor to about 0.3 parts solvent; and

(b) adding an aqueous solution comprising a water soluble passenger molecule to said solvent diluted stock solution, whereby an NLP assembly population is formed having a mean particle diameter from about 30 to 200 nm; and wherein the concentration of said solvent in said NLPs is from about 0.5% to about 14%.

2. The method of claim 1 , wherein said diluting of said precursor solution with said ethanol solvent is at a ratio of about 1 part precursor to about 10 parts solvent to about 1 part loaded vehicle population to about 0.5 parts solvent.

3. The method of claim 1 , wherein said precursor solution comprises phospholipids selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI) and mixtures thereof.

4. The method of claim 1 , wherein said phospholipids consist of a mixture of phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI).

5. The method of claim 3 , wherein said phospholipids consist of a mixture of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI).

6. The method of claim 5 , wherein the ratio of said phospholipids in said mixture is PC:PE:PA:PI of 6.5:2.5:0.7:0.3.

7. The method of claim 1 , comprising making one or more additional dilutions of said precursor solution with said ethanol solvent in order to provide a desired size of NLPs and number of NLPs per unit volume.

8. The method of claim 1 , wherein said water-soluble passenger molecule is a water-soluble vitamin.

9. The method of claim 8 , wherein said water-soluble vitamin is Vitamin C.

Assignments (3)
SECURITY INTEREST Recorded Apr 19, 2017
From: NUVESSL INC.
To: COMMUNITY OPPORTUNITY FOUNDATION OF ALBERTA
Reel/Frame 042065/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2017
From: DERMAZONE SOLUTIONS, INC.
To: NUVESSL INC.
Reel/Frame 041573/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2010
From: FOUNTAIN, MICHAEL W
To: DERMAZONE SOLUTIONS, INC.
Reel/Frame 024782/0339 →
Continuity (3)
Continuation 11644281 · Dec 22, 2006
Provisional Application 60755171 · Dec 30, 2005
Related Publication 20100239686A1 · Sep 23, 2010